Henry Rohrs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Henry Rohrs has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Michael L. Gross
Washington University in St. Louis
2 shared publications Aasha M. Turner
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
1 shared publication- Akshay Sankar
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
1 shared publication Alevtina Pavlenco
Donnelly Centre for Cellular and Biomolecular Research, Banting and Best Department of Medical Research, University of Toronto, 816-160 College Street, Toronto, Ontario M5S 3E1, Canada
1 shared publication- Alexander W. Ying
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
1 shared publication Anish Suri
Department of Pathology and Immunology
1 shared publication
Latest Publications
- Top Cited Papers
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eaeb3627
A SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Mammalian switch/sucrose nonfermenting (mSWI/SNF) chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT [SWI/SNF immunoglobulin fold (Ig-fold) for transcription factor interactions], a conserved transcription factor (TF) binding domain on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of the PU.1 TF. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent human cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-“addicted” cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type– and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.
- 2 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 392 (6793) , eaeb3627
Top Cited PapersA SWI/SNF-specific Ig-like domain, SWIFT, is a transcription factor binding platform
Mammalian switch/sucrose nonfermenting (mSWI/SNF) chromatin remodeling complexes modulate DNA accessibility and gene expression; however, their genomic targeting mechanisms remain incompletely understood. Here, we identify SWIFT [SWI/SNF immunoglobulin fold (Ig-fold) for transcription factor interactions], a conserved transcription factor (TF) binding domain on the SMARCD subunits. SWIFT is necessary and sufficient for direct engagement with the transactivation domain of the PU.1 TF. A single amino acid mutation disrupts PU.1-mSWI/SNF binding, impairs complex targeting, and attenuates oncogenic transcription and proliferation in PU.1-dependent human cancer cells. Dominant expression of the SWIFT domain in isolation sequesters TFs from mSWI/SNF and poisons TF-“addicted” cancer cells. Finally, TFs across diverse families interact with SMARCD paralog-specific SWIFT domains. These results define a major mechanism of cell type– and disease-specific mSWI/SNF chromatin targeting and inform approaches toward therapeutic modulation.
- Open Access
- 23 May 2019
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 5 (8) , 1385-1396
Inhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody
Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 Å resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.
- 23 May 2019
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 5 (8) , 1385-1396
Open AccessInhibition of Marburg Virus RNA Synthesis by a Synthetic Anti-VP35 Antibody
Marburg virus causes sporadic outbreaks of severe hemorrhagic fever with high case fatality rates. Approved, effective, and safe therapeutic or prophylactic countermeasures are lacking. To address this, we used phage display to engineer a synthetic antibody, sFab H3, which binds the Marburg virus VP35 protein (mVP35). mVP35 is a critical cofactor of the viral replication complex and a viral immune antagonist. sFab H3 displayed high specificity for mVP35 and not for the closely related Ebola virus VP35. sFab H3 inhibited viral-RNA synthesis in a minigenome assay, suggesting its potential use as an antiviral. We characterized sFab H3 by a combination of biophysical and biochemical methods, and a crystal structure of the complex solved to 1.7 Å resolution defined the molecular interface between the sFab H3 and mVP35 interferon inhibitory domain. Our study identifies mVP35 as a therapeutic target using an approach that provides a framework for generating engineered Fabs targeting other viral proteins.
- Open Access
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 1068.9
A role for major histocompatibility complex (MHC) class II molecules in MHC class I presentation and CD8 T cell priming
The CD4 T cell response against hen egg lysozyme (HEL) in non‐obese diabetic (NOD) mice comprises a majority of T cells reactive against HEL 11–25 despite the presence of another epitope, HEL 20–35, that binds to A g7 with comparable affinity. To investigate further the relationship between peptide affinity and the T cell response, we used ELISPOT to measure cytokine production after priming with HEL. As expected, HEL immunization of NOD mice generated HEL 11–25‐reactive CD4 T cells that secreted interleukin‐2 (IL2) and interferon‐γ (IFNγ). Surprisingly, HEL immunization also gave rise to a robust CD8 T cell response specific for HEL 23–31 presented by D b . Another interesting aspect of these studies was the finding that mice expressing D b but lacking A g7 showed a reduced or absent CD8 T cell response after HEL immunization. A lack of CD4 T cell help could not explain this result, as depletion of CD4 T cells prior to immunization with HEL had a minimal effect on CD8 T cell priming. To test the global effect of MHC class II molecules on MHC class I peptide selection, we have initiated mass spectrometry studies on peptides bound to K d in the presence or absence of A g7 . Initial results indicate a substantial difference in the K d peptide repertoire between cell lines with and without A g7 expression. Altogether, these data suggest a cooperativity between MHC class I and II that affects T cell priming and peptide selection.
- 1 March 2008
- Published by Wiley in The FASEB Journal
- Vol. 22 (S1) , 1068.9
Open AccessA role for major histocompatibility complex (MHC) class II molecules in MHC class I presentation and CD8 T cell priming
The CD4 T cell response against hen egg lysozyme (HEL) in non‐obese diabetic (NOD) mice comprises a majority of T cells reactive against HEL 11–25 despite the presence of another epitope, HEL 20–35, that binds to A g7 with comparable affinity. To investigate further the relationship between peptide affinity and the T cell response, we used ELISPOT to measure cytokine production after priming with HEL. As expected, HEL immunization of NOD mice generated HEL 11–25‐reactive CD4 T cells that secreted interleukin‐2 (IL2) and interferon‐γ (IFNγ). Surprisingly, HEL immunization also gave rise to a robust CD8 T cell response specific for HEL 23–31 presented by D b . Another interesting aspect of these studies was the finding that mice expressing D b but lacking A g7 showed a reduced or absent CD8 T cell response after HEL immunization. A lack of CD4 T cell help could not explain this result, as depletion of CD4 T cells prior to immunization with HEL had a minimal effect on CD8 T cell priming. To test the global effect of MHC class II molecules on MHC class I peptide selection, we have initiated mass spectrometry studies on peptides bound to K d in the presence or absence of A g7 . Initial results indicate a substantial difference in the K d peptide repertoire between cell lines with and without A g7 expression. Altogether, these data suggest a cooperativity between MHC class I and II that affects T cell priming and peptide selection.
- 1 April 2004
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 23 (4) , 314-321
Integration test of a miniature ExB mass spectrometer with a gas chromatograph for development of a low-cost, portable, chemical-detection system
- 1 April 2004
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 23 (4) , 314-321
Integration test of a miniature ExB mass spectrometer with a gas chromatograph for development of a low-cost, portable, chemical-detection system
- 25 September 2000
- Published by American Physical Society (APS) in Physical Review Letters
- Vol. 85 (13) , 2701-2704
New Experimental Test of the Pauli Exclusion Principle Using Accelerator Mass Spectrometry
We report the results of a new experimental search for the Pauli-forbidden state of Be, denoted by . Using the Accelerator Mass Spectrometer facility at Purdue University, we set limits on the abundance of in metallic Be, Be ore, natural gas, and air. Our results improve on those obtained in a previous search for by a factor of approximately 300.- 25 September 2000
- Published by American Physical Society (APS) in Physical Review Letters
- Vol. 85 (13) , 2701-2704
New Experimental Test of the Pauli Exclusion Principle Using Accelerator Mass Spectrometry
We report the results of a new experimental search for the Pauli-forbidden state of Be, denoted by . Using the Accelerator Mass Spectrometer facility at Purdue University, we set limits on the abundance of in metallic Be, Be ore, natural gas, and air. Our results improve on those obtained in a previous search for by a factor of approximately 300.